Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Lung Therapeutics, Inc
- Target Recruit Count
- 71
- Registration Number
- NCT04233814
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Lung Therapeutics, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT04159831
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath